More Biotech IPOs Likely To Rely On Insiders Amid Slump

Law360, New York (February 19, 2016, 2:20 PM EST) -- As the initial public offerings market continues to trudge through a cold winter, more biotechs are relying on support from inside investors to close deals, a trend capital markets attorneys expect will be necessary to sustain activity given weaker demand in the broader market.

Data tracked by IPO researcher Renaissance Capital shows that among four IPOs this year — all generated by biotechs — insiders publicly indicated interest in buying shares amounting to about 31 percent of proceeds, up from 22 percent in 2015.

The trend toward insider buying comes as companies find it harder to persuade new investors amid chilly...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS